Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis

Cluster of differentiation 44 (CD44) is a transmembrane glycoprotein that serves as the receptor for the extracellular matrix component hyaluronic acid. CD44 has been reported to play key roles in cell proliferation, motility, and survival, but its role in breast cancer remains controversial. In thi...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2016-01, Vol.9, p.431-444
Main Authors: Xu, Hanxiao, Tian, Yijun, Yuan, Xun, Liu, Yu, Wu, Hua, Liu, Qian, Wu, Gen Sheng, Wu, Kongming
Format: Article
Language:English
Subjects:
Breast cancer
Cancer cells
Care and treatment
Cell adhesion & migration
Cell growth
Datasets
Development and progression
Gene expression
Genetic aspects
Glycoproteins
Health aspects
Medical prognosis
Membrane proteins
Messenger RNA
Meta-analysis
Metastasis
Oncology
Original Research
Patients
Proteins
Statistical analysis
Stem cells
Studies
Tumorigenesis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cluster of differentiation 44 (CD44) is a transmembrane glycoprotein that serves as the receptor for the extracellular matrix component hyaluronic acid. CD44 has been reported to play key roles in cell proliferation, motility, and survival, but its role in breast cancer remains controversial. In this study, we conducted a meta-analysis. A total of 23 published Gene Expression Omnibus databases were included to evaluate the association between CD44 mRNA expression and clinicopathological characteristics or prognosis of the patients with breast cancer. Our analysis revealed that CD44 expression was associated with clinicopathological features, including the histological grade, estrogen receptor status, progesterone receptor status, and human epidermal growth factor receptor-2 status. Higher levels of CD44 expression were observed in the basal subtype of breast cancer both at the mRNA and protein levels (odds ratio [OR] =2.08, 95% confidence interval [CI]: 1.72-2.52; OR =2.11, 95% CI: 1.67-2.68). Patients with CD44 overexpression exhibited significantly worse overall survival (hazard ratio =1.27; 95% CI: 1.04-1.55). Whole gene profile analysis revealed that CD44 expression was enriched in basal-type breast cancer and correlated with epithelial-mesenchymal transition and cancer stem cell gene profiles. In summary, our analyses indicated that CD44 potentially might be a prognostic marker for breast cancer and thus can serve as a therapeutic target for basal-type breast cancer.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S97192